BioNTech schedules November 3 results. BioNTech stock sits 29.27 percent below its high

Published on 10/17/2026 at 19:36 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Second-quarter revenue fell to USD 122.31 million in 2026. BioNTech stock was EUR 77.95 on October 16, 2026 at 9:57 p.m. CEST.

Revenue and reporting date

BioNTech is scheduled to report results on November 3, 2026.
Second-quarter revenue fell 59.50 percent year over year to USD 122.31 million.
BioNTech stock was last at EUR 77.95 on Tradegate on October 16, 2026 at 9:57 p.m. CEST.
BioNTech had a USD 22.0 billion market capitalization and a negative P/E ratio of 11.57 as of October 16, 2026.

BioNTech SE, US09075V1026, Illustration mit AI erstellt.

BioNTech has scheduled its next results for November 3, 2026, according to MetaCap. The date gives investors a fixed point for judging whether the company's oncology pipeline can offset weaker vaccine revenue. BioNTech stock was last at EUR 77.95 on Tradegate on October 16, 2026 at 9:57 p.m. CEST.

Revenue remains the key test

BioNTech's second-quarter revenue fell 59.50 percent year over year to USD 122.31 million, while the company reported a net loss of USD 820.80 million for the period. MarketBeat reported that revenue missed a USD 180.18 million consensus estimate. The comparison matters because BioNTech's transition toward cancer medicines is being measured against a smaller commercial contribution from COVID products.

Stock remains below its yearly high

On Nasdaq, BioNTech last traded at USD 87.71 on October 16, 2026 at 4:00 p.m. ET. The same quote showed a 52-week high of USD 124.00 and a 52-week low of USD 79.52, putting the share 29.27 percent below its high and 10.30 percent above its low. The figures describe the stock's position in its home-market currency, while the German price provides the euro perspective for local investors.

Valuation and reporting date

BioNTech had a market capitalization of USD 22.0 billion and a trailing negative P/E ratio of 11.57 as of October 16, 2026. Its cash and cash equivalents stood at USD 9.74 billion at the end of the second quarter of 2026, against total assets of USD 20.34 billion. The November 3 reporting date is the next scheduled company event identified in the cited calendar, and the quarterly figures will provide the next measurable update on revenue and losses.

Comparison with peers

BioNTech SE: P/E minus 11.57, market capitalization USD 22.0 billion.
Moderna, Inc.: minus 7.82 percent daily change, P/E minus 27.32, market capitalization USD 87.0 billion.
Gilead Sciences, Inc.: minus 0.75 percent daily change, P/E minus 58.50, market capitalization USD 193.7 billion.

Price and dates

The October 16 quotation places BioNTech below its yearly high while leaving the November 3 results date as the next scheduled checkpoint. The company had USD 9.74 billion in cash at the end of the second quarter, giving the balance sheet an important role alongside the revenue trend.

The further course of trading is shown by the continuously updated real-time quote of BioNTech stock.